Progenics Pharmaceuticals Inc. stock performance trend indicates that the stock price has rallied 16.3% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 75.83% . Looking at the past 52 week period, the stock price is up at 170.15% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Progenics Pharmaceuticals Inc. has a positive value of 67.99 compared to overall market.Progenics Pharmaceuticals, Inc. is having a Relative Strength Index of 56.74 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) has tumbled 3.05% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 4.8% in the last four weeks. The stocks have underperformed the S&P 500 by 3.28% during the past week but Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) it has outperformed the index in 4 weeks by 3.61%.
For this week, the average consensus of the stock is rated as a Strong Buy. Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.31 points or 2.71% at $11.13 with 1,857,908 shares getting traded. Post opening the session at $11.4, the shares hit an intraday low of $10.9 and an intraday high of $11.41 and the price was in this range throughout the day. The company has a market cap of $781 million and the number of outstanding shares has been calculated to be 70,190,099 shares. The 52-week high of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) is $11.72 and the 52-week low is $3.8.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Upgraded by Needham on Feb 6, 2017 to Strong Buy, Raises Price Target to $ 14 from a previous price target of $11 .
Company has reported several Insider transactions to the SEC, on Apr 22, 2016, Paul J Maddon (director) purchased 5,000 shares at 4.90 per share price.On Jun 15, 2015, Robert J Israel (Executive Vice President, Medi) sold 2,000 shares at 6.83 per share price.
Progenics Pharmaceuticals Last issued its quarterly earnings results on Mar 9, 2017. The company reported $-0.10 EPS for the quarter, beating the analyst consensus estimate by $ 0.10. Analyst had a consensus of $-0.20. The company had revenue of $4.65 million for the quarter, compared to analysts expectations of $4.43 million. The companys revenue was down -8.8 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.10 EPS.
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.